MAR 22, 2020 7:48 AM PDT

What is "Shotgun ion mobility mass spectrometry sequencing"?

Research published recently in Nature Communications highlights a new method of mapping an essential family of polysaccharides called GAGs (glycosaminoglycans). GAGs are critical to regulating many biological functions such as inflammation, neurodegeneration and tumor metastasis. One common type of GAG is called heparin and is currently used in clinical settings in an anticoagulant drug. Yet, aside from heparin, to date GAGs have been difficult to understand and only several structures have been accurately mapped.

Now the study from the Danish National Research Foundation Centre for Glycomics at the Department of Cellular and Molecular Medicine, University of Copenhagen, offers new insight on GAG mapping methods.

Photo: Pixabay

"Determining the structures is a key question in the research about sugars. If we know the structure, we can determine what the cues are for specific biological functions and consider potential ways to exploit this in the development of therapeutics. This is hugely important and clinically relevant, as shown by the widely used anti-coagulant heparins, and the potential application of new heparin-based drugs for multiple diseases in the future," says the corresponding author, Dr. Rebecca Louise Miller, who is an Assistant Professor at the Copenhagen Center for Glycomics.

The method that Dr. Miller and her team have developed is called "Shotgun ion mobility mass spectrometry sequencing" or SIMMS2. It’s a complicated name and an even more complicated process akin to breaking sugar structures into small puzzle pieces in order to identify their genetic fingerprints and compare them to know existing structures. Through this process, they are able to sequence larger GAG structures.

"The instrumentation behind this new method was invented by the company Waters Ltd in 2006 and is available to many pharmaceutical companies and researchers. This means that the method could be easily implemented and widely used for drug discovery by many research groups in a short period of time," says co-author Professor Jeremy Turnbull, University of Liverpool and Copenhagen Center for Glycomics.

The researchers plan to continue their investigations with GAGs, SIMMS2, and GAGOme (another method they developed) in hopes of improving the therapeutic effects of heparins in cancer and neurogenerative diseases like Parkinson’s.

Sources: Nature Communications, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAR 31, 2020
Cancer
MAR 31, 2020
Ovarian cancer metastasis and CPT1A
Research published in the journal Molecular Cancer Research from collaborators at the University of Colorado C ...
APR 19, 2020
Drug Discovery & Development
APR 19, 2020
FDA Approves New Drug for Breast Cancer
The US Food and Drug Administration has approved a new drug, known as tucatinib or Tuksya, as a treatment for advanced f ...
MAY 19, 2020
Cancer
MAY 19, 2020
Great ape genomes closer to human tumors than human genomes
A new study analyzing cancer from an evolutionary perspective reports that the distribution of mutations in human tumors ...
MAY 21, 2020
Cancer
MAY 21, 2020
When is the best time to talk about end-of-life decisions with your teen who has cancer?
A study published recently in JAMA Network highlights the need for improved pediatric advanced care for adolescents with ...
MAY 22, 2020
Cancer
MAY 22, 2020
Even minimal exercise can reduce breast cancer recurrence
New research urges individuals at high-risk of breast cancer to get moving, shaking, shimmying, and kicking! According t ...
MAY 23, 2020
Cancer
MAY 23, 2020
Can metformin treat lymphoma?
A popular diabetes medication may be useful in treating cancer, according to new research published recently in Cell Rep ...
Loading Comments...